VSL#3 probiotic treatment decreases bacterial translocation in rats with carbon tetrachloride-induced cirrhosis

Liver International

Volumn 35, Issue 3, 2015, Pages 735-745

  Sánchez, Elisabet ^a,b,d,e   Nieto, Juan C ^a,b,e   Boullosa, Ana ^c   Vidal, Silvia ^a,b,e   Sancho, Francesc J ^a   Rossi, Giacomo ^f   Sancho Bru, Pau ^c,d   Oms, Rosa ^a   Mirelis, Beatriz ^a,e   Juárez, Cándido ^a,e   Guarner, Carlos ^a,b,d,e   Soriano, Germán ^a,b,d,e  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b BIOMEDICAL RESEARCH INSTITUTE SANT PAU IIB SANT PAU   (Spain)

^c HOSPITAL CLÍNIC   (Spain)

^d INSTITUTO DE SALUD CARLOS III   (Spain)

^e UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^f UNIVERSITY OF CAMERINO   (Italy)

Author keywords

Experimental model; Inflammatory response; Intestinal barrier; Liver damage; Microbiota

Indexed keywords

CARBON TETRACHLORIDE; CLAUDIN 2; CLAUDIN 4; DEFENSIN; MALONALDEHYDE; OCCLUDIN; PROBIOTIC AGENT; VSL3; RENIN; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ASCITES; BACTERIAL TRANSLOCATION; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFECT; ENTEROBACTERIACEAE; ENTEROCOCCUS; INFLAMMATION; INTESTINE EPITHELIUM; INTESTINE FLORA; LIVER CIRRHOSIS; MALE; MORTALITY; NONHUMAN; PROTEIN EXPRESSION; RAT; ANIMAL; BLOOD; CHEMICALLY INDUCED; DISEASE MODEL; DRUG EFFECTS; INTESTINE MUCOSA; LAPAROTOMY; LIVER CIRRHOSIS, EXPERIMENTAL; METABOLISM; MICROBIOLOGY; SPRAGUE DAWLEY RAT;

ANIMALS; ASCITES; BACTERIAL TRANSLOCATION; CARBON TETRACHLORIDE; DISEASE MODELS, ANIMAL; INTESTINAL MUCOSA; LAPAROTOMY; LIVER CIRRHOSIS, EXPERIMENTAL; MALE; MALONDIALDEHYDE; PROBIOTICS; RATS; RATS, SPRAGUE-DAWLEY; RENIN; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84922636079     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12566     Document Type: Article

References (53)

1. Wiest R, Lawson M, Geuking M. Pathological bacterial translocation in liver cirrhosis. J Hepatol 2014; 60: 197-209.
2. Guarner C, Soriano G. Bacterial translocation and its consequences in patients with cirrhosis. Eur J Gastroenterol Hepatol 2005; 17: 27-31.
3. Bellot P, Frances R, Such J. Pathological bacterial translocation in cirrhosis: pathophysiology, diagnosis and clinical implications. Liver Int 2013; 33: 31-9.
4. Shawcross DL, Shabbir SS, Taylor NJ, Hughes RD. Ammonia and the neutrophil in the pathogenesis of hepatic encephalopathy in cirrhosis. Hepatology 2010; 51: 1062-9.
5. Guarner C, Runyon BA, Young S, Heck M, Sheikh MY. Selective intestinal decontamination with trimethoprim-sulfamethoxazole in an experimental model of cirrhosis in rats. Dig Dis Sci 1999; 44: 1957-1862.
6. Bauer TM, Fernández J, Navasa M, Vila J, Rodés J. Failure of Lactobacillus spp. to prevent bacterial translocation in a rat model of experimental cirrhosis. J Hepatol 2002; 36: 501-6.
7. Fernández J, Acevedo J, Castro M, et al. Prevalence and risk factors of infections by multiresistant bacteria in cirrhosis: a prospective study. Hepatology 2012; 55: 1551-61.
8. Pérez-Páramo M, Muñoz J, Albillos A, et al. Effect of propranolol on the factors promoting bacterial translocation in cirrhotic rats with ascites. Hepatology 2000; 31: 43-8.
9. Lorenzo-Zúñiga V, Bartolí R, Planas R, et al. Oral bile acids reduce bacterial overgrowth, bacterial translocation, and endotoxemia in cirrhotic rats. Hepatology 2003; 37: 551-7.
10. Pardo A, Bartolí R, Lorenzo-Zúñiga V, et al. Effect of cisapride on intestinal bacterial overgrowth and bacterial translocation in cirrhosis. Hepatology 2000; 31: 858-63.
11. Chiva M, Soriano G, Rochat I, et al. Effect of Lactobacillus johnsonii La1 and antioxidants on intestinal flora and bacterial translocation in rats with experimental cirrhosis. J Hepatol 2002; 37: 456-62.
12. Sanders ME, Guarner F, Guerrant R, et al. An update on the use and investigation of probiotics in health and disease. Gut 2013; 62: 787-96.
13. Jonkers D, Stockbrügger R. Review article: probiotics in gastrointestinal and liver diseases. Aliment Pharmacol Ther 2007; 26(Suppl. 2): 133-48.
14. Lata J, Jurankova J, Kopacova M. Probiotics in hepatology. World J Gastroenterol 2011; 17: 2890-6.
15. Sheth AA, García-Tsao G. Probiotics and liver disease. J Clin Gastroenterol 2008; 42(suppl. 2): S80-4.
16. Soriano G, Sánchez E, Guarner C, Schiffrin E. Lactobacillus johnsonii La1 without antioxidants do not decrease bacterial translocation in rats with carbon tetrachloride-induced cirrhosis. J Hepatol 2012; 57: 1395-6.
17. Wiest R, Chen F, Cadelina G, Groszmannn RJ, García-Tsao G. Effect of Lactobacillus-fermented diets on bacterial translocation and intestinal flora in experimental prehepatic portal hypertension. Dig Dis Sci 2003; 48: 1136-41.
18. Liu Q, Duan ZP, Ha DK, et al. Synbiotic modulation of gut flora: effect on minimal hepatic encephalopathy in patients with cirrhosis. Hepatology 2004; 39: 1441-9.
19. Loguercio C, Federico A, Tuccillo C, et al. Beneficial effects of a probiotic VSL#3 on parameters of liver dysfunction in chronic liver diseases. J Clin Gastroenterol 2005; 39: 540-3.
20. Mennigen R, Nolte K, Rijcken E, et al. Probiotic mixture VSL#3 protects the epithelial barrier by maintaining tight junction protein expression and preventing apoptosis in a murine model of colitis. Am J Physiol Gastrointest Liver Physiol 2009; 296: G1140-9.
21. Caballero-Franco C, Keller K, De Simone C, Chadee K. The VSL#3 probiotic formula induces mucin gene expression and secretion in colonic epithelial cells. Am J Physiol Gastrointest Liver Physiol 2007; 292: G315-22.
22. Madsen K, Cornish A, Soper P, et al. Probiotic bacteria enhance murine and human intestinal epithelial barrier function. Gastroenterology 2001; 121: 680-591.
23. Velayudham A, Dolganiuc A, Ellis M, et al. VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice. Hepatology 2009; 49: 989-97.
24. Agrawal A, Sharma BC, Sharma P, Sarin SK. Secondary prophylaxis of hepatic encephalopathy in cirrhosis: an open-label, randomized controlled trial of lactulose, probiotics, and no therapy. Am J Gastroenterol 2012; 107: 1043-50.
25. Lunia MK, Sharma BC, Sharma P, Sachdeva S, Srivastava S. Probiotics prevent hepatic encephalopathy in patients with cirrhosis: a randomized controlled trial. Clin Gastroenterol Hepatol 2014; 12: 1003-8.e1
26. Runyon BA, Sugano S, Kanel G, Mellencamp MA. A rodent model of cirrhosis, ascites and bacterial peritonitis. Gastroenterology 1991; 100: 489-93.
27. Runyon BA, Squier S, Borzio M. Translocation of gut bacteria in rats with cirrhosis to mesenteric lymph nodes partially explains the pathogenesis of spontaneous bacterial peritonitis. J Hepatol 1994; 21: 792-6.
28. Gupta N, Kumar A, Sharma P, et al. Effects of the adjunctive probiotic VSL#3 on portal haemodynamics in patients with cirrhosis and large varices: a randomized trial. Liver Int 2013; 33: 1148-57.
29. García-Tsao G, Lee FY, Barden GE, Cartun R, West AB. Bacterial translocation to mesenteric lymph nodes is increased in cirrhotic rats with ascites. Gastroenterology 1995; 108: 1835-41.
30. Chiva M, Guarner C, Peralta C, et al. Intestinal mucosal oxidative damage and bacterial translocation in cirrhotic rats. Eur J Gastroenterol Hepatol 2003; 15: 145-50.
31. Closa D, Bulbena O, Roselló-Catafau J, Fernández-Cruz L, Gelpí E. Effect of prostaglandins and superoxide dismutase administration on oxygen free radical production in experimental acute pancreatitis. Inflammation 1993; 17: 563-71.
32. Rossi G, Nigro G, Tattoli I, et al. Adhesion molecules and cytokine profile in ileal tissue of sheep infected with Mycobacterium avium subsp. paratuberculosis. Microbes Infect 2009; 11: 698-706.
33. Moratalla A, Gómez-Hurtado I, Santacruz A, et al. Protective effect of Bifidobacterium pseudocatenulatum CECT7765 against induced bacterial antigen translocation in experimental cirrhosis. Liver Int 2014; 34: 850-8.
34. Proctor E, Chatamra K. High yield micronodular cirrhosis in the rat. Gastroenterology 1982; 83: 1183-90.
35. Guarner C, Runyon BA, Young S, Heck M, Sheikh MY. Intestinal bacterial overgrowth and bacterial translocation in cirrhotic rats with ascites. J Hepatol 1997; 26: 1372-8.
36. Venturi A, Gionchetti P, Rizzello F, et al. Impact on the composition of the faecal flora by a new probiotic preparation: preliminary data on maintenance treatment of patients with ulcerative colitis. Aliment Pharmacol Ther 1999; 13: 1103-8.
37. Kühbacher T, Ott SJ, Helwig U, et al. Bacterial and fungal microbiota in relation to probiotic therapy (VSL#3) in pouchitis. Gut 2006; 55: 833-41.
38. Pijls KE, Jonkers DM, Elamin EE, Masclee AA, Koek GH. Intestinal epithelial function in liver cirrhosis: an extensive review of the literature. Liver Int 2013; 33: 1457-69.
39. Asmakopoulos SF, Tsamandas AC, Tsiaoussis G, et al. Altered intestinal tight junctions' expression in patients with liver cirrhosis: a pathogenic mechanism of intestinal hyperpermeability. Eur J Clin Invest 2012; 42: 439-46.
40. Yang DH, Ye ZY, He XJ, Xu WJ, Zhou WM. Effect of salvianolate on intestinal epithelium tight junction protein zonula occludens protein 1 in cirrhotic rats. World J Gastroenterol 2012; 18: 7040-7.
41. Du Plessis J, Vanheel H, Janssen CE, et al. Activated intestinal macrophages in patients with cirrhosis release NO and IL-6 that may disrupt intestinal barrier function. J Hepatol 2013; 58: 1125-32.
42. Schlee M, Harder J, Koten B, et al. Probiotic lactobacilli and VSL#3 induce enterocyte beta-defensin 2. Clin Exp Immunol 2008; 151: 528-35.
43. Bielefeldt K, Conklin JL. Intestinal motility during hypoxia and reoxygenation in vitro. Dig Dis Sci 1997; 42: 878-84.
44. Ramachandran A, Prabhu R, Thomas S, et al. Intestinal mucosal alterations in experimental cirrhosis in the rat: role of oxygen free radicals. Hepatology 2002; 35: 622-9.
45. Esposito E, Iacono A, Blanco G, et al. Probiotics reduce the inflammatory response induced by a high-fat diet in the liver of young rats. J Nutr 2009; 139: 905-11.
46. Wiest R, Das S, Cadelina G, et al. Bacterial translocation in cirrhotic rats stimulates eNOS-derived NO production and impairs mesenteric vascular contractility. J Clin Invest 1999; 104: 1223-33.
47. Francés R, Chiva M, Sánchez E, et al. Bacterial translocation is downregulated by an anti-TNF-alpha monoclonal antibody administration in rats with cirrhosis and ascites. J Hepatol 2007; 46: 797-803.
48. López-Talavera JC, Merrill WW, Groszmann RJ. Tumor necrosis factor alpha: a major contributor to the hyperdynamic circulation in prehepatic portal-hypertensive rats. Gastroenterology 1995; 108: 761-7.
49. Rincón D, Vaquero J, Hernando A, et al. Oral probiotics VSL#3 attenuates the circulatory disturbances of patients with cirrhosis and ascites. Liver Int 2014; 34: 1504-12.
50. Jayakumar S, Carbonneau M, Hotte N, et al. VSL#3 probiotic therapy does not decrease portal pressures in patients with decompensated cirrhosis. Liver Int 2013; 33: 1470-7.
51. Seki E, Schnabl B. Role of innate immunity and the microbiota in liver fibrosis: crosstalk between the liver and gut. J Physiol 2012; 590: 447-58.
52. D'Argenio G, Cariello R, Tuccillo C, et al. Symbiotic formulation in experimentally induced liver fibrosis in rats: intestinal microbiota as a key point to treat liver damage. Liver Int 2013; 33: 687-97.
53. Cuenca S, Sanchez E, Santiago A, et al. Microbiome composition by pyrosequencing in mesenteric lymph nodes of rats with CCl4-induced cirrhosis. J Innate Immun 2013; 6: 263-71.